Feb 01, 2024 / 01:15PM GMT
Mark Douglas Purcell - Morgan Stanley, Research Division - Equity Analyst
My name is Mark Purcell from Morgan Stanley. It gives me great pleasure to introduce you to the Novo Nordisk management team here at the London Full Year Results Investor Presentation. We have everybody here I think.
And Lars, I'll hand over to you to start the presentation.
Lars Fruergaard Jorgensen - Novo Nordisk A/S-President - CEO & Member of Management Board
Thank you, Mark, and thank you to Morgan Stanley for hosting us today. We are glad to be here and we'll do a quick presentation upfront and then get into Q&A. I have to warn you that we'll be talking about the future so please take due notice to the forward-looking disclaimer on this slide. So overall on performance, we're really pleased with how we exited 2023. We're making good progress on our strategic aspirations. 2023 was a year where we stepped up the number of patients by 5 million and just in context we are now serving in total some 42 million. So 5 million more
Q4 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot